FindTrial
Sign In

Research on Ultrasound Radiomics of HER-2 Positive Breast Cancer

Research on the Application of Predicting HER-2 Positive Breast Cancer Based on Intratumoral and Peritumoral Ultrasound Radiomics Combined with Deep Learning

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112747
Enrollment
Unknown
Registered
2025-11-19
Start date
2024-08-17
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER-2 positive breast cancer

Interventions

HER-2(+) Group:None
HER-2(-) Group:None

Sponsors

Gongli Hospital of Shanghai Pudong New Area
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients with breast cancer confirmed by postoperative pathology; 2.The molecular immunohistochemical data of breast cancer were complete; 3.Preoperative ultrasonography was performed and the image data were clear and complete; 4.No relevant antitumor therapy was given before operation;

Exclusion criteria

Exclusion criteria: 1.Receive any intervention and treatment before breast ultrasound; 2.The lesion exceeded the maximum scanning range of the probe; 3.Patients whose images are of poor quality and cannot be used for analysis;

Design outcomes

Primary

MeasureTime frame
Human Epidermal Growth Factor Receptor 2 expression status;Estrogen receptor;Progesterone receptor;Ki-67 Proliferation Index;—

Countries

China

Contacts

Public ContactFu Xiaohong

Gongli Hospital of Shanghai Pudong New Area

fuxiaohong66@163.com+86 18916157425

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026